Beliefs about cholesterol lowering drugs and medication adherence among Palestinian adults with dyslipidemia in Ramallah and Bethlehem areas of the West Bank by جهاد خليل احمد شكارنه & JIHAD KHALIL AHMAD SHAKARNA
 
 
 
Al-Quds University  
Deanship of Graduate Studies 
 
 
Beliefs about Cholesterol Lowering Drugs and Medication 
Adherence Among Palestinian Adults with Dyslipidemia 
in Ramallah and Bethlehem areas of the West Bank 
 
 
 
 
Jihad Khalil Ahmad Shakarna 
 
M.Sc. Thesis 
 
Jerusalem, Palestine  
 
1441/2019 
 
 
 
Beliefs about Cholesterol Lowering Drugs and Medication 
Adherence Among Palestinian Adults with Dyslipidemia in 
Ramallah and Bethlehem areas of the West Bank 
 
 
 
Prepared by: 
Jihad Khalil Ahmad Shakarna 
  
B.Sc.: Pharmacy from Al-Quds University, Abu- Dis  
 
 
Supervisor: Dr. Hussein Hallak  
 
This thesis is submitted in partial fulfillment of the 
requirements for the degree of Master of Pharmaceutical 
science in Pharmacy Department. 
 
 
Al-Quds University  
 
1441/2019 

 
 
Dedication 
 
I dedicate my graduation project to those who harvested thorns from my 
way to pave the path of science to the great hearts to my parents. 
 
To my lovely husband for his endless support and encouragement. To my 
beloved children Khaled and Mesk who give me the power and 
inspiration to keep on. 
 
Also to my sisters and brothers, who gave me all the support to complete 
my research step by step. Without their unfailing support and help this 
work would not have been possible. 
 
 
 
 
 
 
 
 
 
 
 
 

ii 
 
 
                                    Acknowledgements 
First of all, I thank Allah for giving me strength and ability to complete 
this project. 
 
Special thanks for my professors for their guidance,  encouragement,  and  
help through this study. 
 
Many thanks also for all workers at health clinics at Ramallah and 
Bethlehem, my thanks for the participants who willingly accepted to 
share for the purpose of this study. 
 
Finally, an honorable mention goes to my family for their understandings 
and supports for me in completing this project, the product of this project 
would not be possible without all of them. 
   
  
 
 
 
 
 
 
iii 
 
 
Table Contests 
 
Table of Contents 
Dedication ....................................................................................... V 
Declaration ....................................................................................... i 
Acknowledgements .......................................................................... ii 
Table Contests ................................................................................ iii 
List of Tables ................................................................................... v 
List of Figures ................................................................................. vi 
List of Abbreviations ....................................................................... vii 
Chapter one ............................................................................... 1 
Introduction ............................................................................... 1 
1.1. Dyslipidemia ........................................................................ 1 
1.2 Types of dyslipidemia: ............................................................ 3 
:Dyslipidemia 1.3 Classification of  ............................................... 4 
Dyslipidemia of 1.4 Causes   ........................................................ 5 
1.5 Symptoms and diagnosis: ....................................................... 5 
1.6 Adherence ............................................................................ 6 
1.8  Prevalence of dyslipidemia .................................................... 9 
1.9 Problem statement: ............................................................. 11 
1.10  General Objectives : .......................................................... 11 
1.11  Specific objectives: ........................................................... 11 
Chapter Two ............................................................................ 13 
Literature review ...................................................................... 13 
2.1 Literature review: ................................................................ 13 
iv 
 
2.2 Significance of study : .......................................................... 16 
Chapter Three ......................................................................... 17 
Methods and Materials ............................................................. 17 
3.1 Study design ....................................................................... 17 
3.2  Study setting ...................................................................... 17 
3.3 Study Participants ............................................................... 17 
procedure and sample size calculation 3.4 Sampling ..................... 18 
3.5 Inclusion and exclusion criteria ............................................. 18 
3.6 Instruments and data collection form .................................... 18 
3.7 Ethical approval .................................................................. 12 
3.8 Pilot study .......................................................................... 11 
3.9  Statistical analysis ............................................................... 11 
Chapter Four ........................................................................... 11 
4.1. Patient characteristics ......................................................... 11 
4.2 Non-adherence behaviors .................................................... 11 
4.3 Beliefs concerning medicines ................................................ 15 
4.4 Association of beliefs with other factors ................................ 17 
Chapter five ................................................................................ 32 
Discussion ................................................................................ 32 
Chapter Six .............................................................................. 35 
Conclusion ............................................................................... 35 
6.1 Strength of our study: .......................................................... 35 
6.2 Recommendation and limitations ......................................... 36 
6.3 Conclusion .......................................................................... 37 
References :- ............................................................................ 38 
Appendices A: .......................................................................... 43 
صخلملا: .................................................................................... 56 
 
v 
 
 
 
Tables 
 
Page Content Table 
4 lipidemiaClassification of Dys 1.1 
 
23 
Patient characteristics and the results of 
the univariate analysis of factors with 
potential impact on medication adherence 
4.2 
 
23 
Adherence and non-Adherence Rates, 
Likely Causes of  non-Adherence among 
Study Participants (n= 185). 
4.3 
28 
 
Adherent and non-adherent patients' 
beliefs about medicines scores 
4.4 
 
28 
Associations of study variables with 
Beliefs about Medicines Necessity 
Specific scores 
4.5 
 
29 
Associations of study variables with 
Beliefs about Medicines Concern Specific 
scores 
4.6 
29 Multiple regression analysis for variables 
predicting non-adherence 
4.7 
 
 
 
 
 
 
 
 
 
vi 
 
 
List of Figures 
 
 
Page Content Figure 
9 Five dimensions of adherence    1.1 
 
25 
Percentage of respondents 
agreeing/strongly agreeing with Beliefs 
about Medicines Questionnaire statements 
(Necessity-statements) 
4.2 
 
26 
Percentage of respondents 
agreeing/strongly agreeing with Beliefs 
about Medicines  Questionnaire statements 
(Concerns -statements) 
4.3 
 
27 
Framework of patients‟ attitudes and 
beliefs about medication 
 
4.4 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
List of Abbreviations 
 
 
 
 
 
 
 
 
Explanation Abbreviation 
Brief medication questionnaire           BMQ 
Coronary heart disease CHD 
Cardiovascular disease  CVD 
High density lipoprotein HDL 
Human immune deficiency HIV 
Institutional review boards  IRB 
Low density lipoprotein  LDL 
Multi ethic study of atherosclerosis  MESA 
Morisky medication adherence scale four items  MMAS-4 
Metabolic syndrome  MS 
Necessity concern differential  NCD 
Non-Communicable Diseases NCDs 
National cholesterol education panels  NCEP 
Necessity concern framework  NCF 
National health and nutr Trying to provide the 
medicine permanently to patients in private health 
centers that it needs permanent and uninterrupted 
treatment for these medicinesition examination 
survey  
NHANES 
Standard deviation  SD 
Statistical package for social sciences  SPSS 
Self-regulatory model  SRM 
Total Cholesterol  TC  
Triglyceride  TG 
World health organization WHO 
viii 
 
Abstract  
Background: 
 Lipid-lowering drugs are widely underused, despite strong evidence indicating they 
improve cardiovascular end points. Poor patient adherence to a medication regimen 
can affect the success of lipid-lowering treatment. 
Objectives: 
The aim of the present study was to assess the level of medication adherence among 
hypelipedimic patient‟s, patient‟s beliefs about medicines and explore the relationship 
between medication adherence and medicines beliefs and other demographic and 
clinical variables in the study participants. 
Methods:  
The study was a cross sectional design conducted between Jan 2019 and July 2019 to 
evaluate the influence of beliefs about medicines, demographic and clinical factors on 
adherence to cholesterol lowering drugs among Palestinians. This study was carried 
out at middle governmental primary healthcare clinics in Ramallah and Bethlehem 
cities. The disease specific tool is Morisky and beliefs about medicine questionnaires 
(BMQ).  
Adherence was measured using self-reported four-item Morisky Medication 
Adherence Scale (MMAS-4) which measures the medication adherence with 
questions 1-4 having dichotomous responses (No =0 score and Yes = 1 score). The 
results were analyzed using Statistical Package for Social Sciences (SPSS) program 
version 21 Multiple linear regression analysis was performed to determine the most 
important variables related to adherence in dyslipidemic patient. 
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Results:  
Of the 220 patients approached, a total of 185 patients agreed  participate in the study 
with a response rate of (84.1%). Of them, 106 (57.3) were men. Almost half of the 
participants 88 (46.5%) were ≥ 56 years.  According to the MMAS-4 scale, 
medication non-adherence was high (47.6%). The majority of the participants (65.5%) 
believed in the necessity of their treatment for maintaining their good health. Mean 
necessity score of 17.3 (S.D. 3.7) was significantly greater than mean concerns score 
of 14.0 (3.5); P<0.001). Multivariate regression demonstrated that 4 variables remain 
significant and associated with non-adherence; illiterate (OR= 2.52; CI: 0.9 – 4.3; 
P=0.03), polypharmacy (OR= 3.18; CI: 1.9-5.7; P=0.007), having comorbidity (OR= 
3.10; CI: 2.2-4.6; P=0.005) and having concerns about side effects (OR= 2.89; CI: 
1.1-4.6, P=0.04) were most likely non-adhere to their medications.  
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Conclusion: 
Non-adherence among patients taking lipid lowering agents was high. Most people 
with hyperlipidemia have positive beliefs about the necessity of their medication. 
However, levels of concern are also high. Physicians should identify and target high 
risk patients and individualize their treatment plan in order to achieve adequate 
control of hyperlipidemia. 
 
 
Key words:  
Hyperlipidemia, Cholesterol, Statin, Adherence, Beliefs,  Palestine, WHO, MMSA-4, 
BMQ, CVD, CHD. 
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Chapter one 
ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ 
Introduction 
1.1. Dyslipidemia  
 
When lipoproteins are overproduced or deficient, the result is a lipoprotein 
metabolism disorder known as dyslipidemia. Elevated total cholesterol is one of the 
culprits of dyslipidemia. Cholesterol is a fat protein that is produced by the liver and 
is necessary to maintain healthy cell membranes, brain function, hormone production, 
and vitamin storage. 
 
The two forms of cholesterol are high-density lipoprotein (HDL) and low-density 
lipoprotein (LDL). As their names suggest, both LDL and HDL are lipoproteins that 
comprise a combination of a lipid and a protein. The lipid portion is bound to 
proteins, for the cholesterol molecules to move through the blood. 
  
LDL and HDL are unique in their function. LDL it is sometimes called “bad 
cholesterol," because high LDL levels cause risk factor for the CAD. In contrast, 
HDL is called as the "good one," because it transfer the cholesterol back to liver, 
which is how cholesterol is removed.  
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A diagnosis of dyslipidemia occurs when the total cholesterol (TC) level is above the 
normal value, or when LDL is generated or eat diary or bad foods [1]. A 
hyperlipidemia patient may show elevated levels of  either  LDL and TG or both.  
Triglycerides are a type of fat found in the blood. TG are associated with coronary 
heart disease. 
 Metabolic syndrome (MS) is a condition when a patient has a variety of medical 
disorders that combined show an increased risk of developing cardiovascular disease 
(CVD). Studies in Middle East showed that MS affects approximately one in four 
people, and its incidence increases with age. Due to reports showing increase 
percentages of MS and its main cardiovascular risk factors (15-60%) among Middle 
Eastern populations, there is a need for national and international programs that 
counter obesity, hypertension, and especially dyslipidemia. Ultimately, it is crutial to 
focus on early prevention and control [2]. 
The treatment of dyslipidemia is clearly prevent primary and secondary heart 
diseases. However, in Europe and the USA, cross-sectional surveys examining factors 
associated with chronic heart disease show that treatment of dyslipidemia remains 
inadequate. Consequently, more studies are necessary to evaluate the present level of 
undertreated dyslipidemia , which occurs when a patient receives a lipid-lowering 
treatment but still has TC and/or LDL-C levels that are uncontrolled, and why some 
patients on suboptimal therapy which consequently prone to CVD.   [3-6]. Thus, the 
aim of this study was to examine the effect of dyslipidemia on the daily life of 
patients by measuring their compliance indices and their adherence to medication. 
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1.2 Types of dyslipidemia: 
Hyperlipidemia is categorized based on the type of fat that is affected and how it 
impacts the body. The main types of hyperlipidemia are described here. 
Type I: This type is severe and typically occurs during childhood. It triggers 
abdominal pain, repeated pancreatic infections, and enlargement of the spleen and 
liver. Occasionally, this type is referred to as familial LPL deficiency, and it is a 
congenital condition that interrupts the normal breakdown of fats. 
Type II(a + b): Type IIa is also referred to as familial hypercholesterolemia and type 
IIb is frequently called familial combined hyperlipidemia. Both types lead to high 
levels of LDL and result in the deposition of fat in the skin and around the eyes. In 
addition these 2 types increase the risk of heart problems. 
Type III: This type is referred to as familial dys beta lipoproteinemia, and it affects 
lipoproteins. These patients experience extremely low LDL levels in the blood, but 
normal HDL levels. Xanthomas, which are flat, yellow-grayish plaques that occur on 
the eyelids and around the eyes, is one of the characteristic features of type III 
hyperlipidemia. Type III , in addition, increases risk of CVD and peripheral artery 
diseases . 
Type IV: This type induces a rise is triglyceride levels in the blood but not 
cholesterol, and the result high BP, Glucose and insulin levels,. This form of the 
disease usually goes undetected until early adulthood.All of the types described above 
can be controlled via dietary measures [7]  
 
4 
 
1.3 Classification of  Dyslipidemia: 
Classification of dyslipidemia is defined by the National Cholesterol Education 
Panel‟s (NCEP). All the concentrations are expressed as mg/dL [8]. 
Table 1.1 Lipid levels  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LDL Cholesterol  
<100 Optimal 
100 – 129 Near or above optimal 
130 – 159 
Borderline high 
160 – 189 High 
≥ 190 Very high 
TC (mmol/L)  
<200 Desirable 
200 – 239 Borderline high 
≥ 240 High  
HDL Cholesterol  
<40 Low 
≥ 60 High 
Triglycerides  
<150 Normal  
150 – 199 Borderline 
200 – 499 High 
≥ 500 Very high 
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1.4 Causes  of  Dyslipidemia 
There are several factors that influence hyperlipidemia: 
 
 Genetic factors: This referred to as primary hyperlipidemia. 
The build up of fat in the blood due to a poor diet, over time, which cause organ 
damage and CVD 
 Alcohol intake 
 BMI and increase weight 
 Some medications like steroids  
 Metabolic disease like DM and CKD 
 an underactive thyroid gland (hypothyroidism) 
 pregnancy 
 
Hereditary dyslipidemia is more common is certain ethnic groups, including French 
Canadians, Christian Lebanese, South African Afrikaners, and Ashkenazi Jews [8]. 
1.5 Symptoms and diagnosis: 
Dyslipidemia typically presents with no obvious signs or symptoms. However, for 
genetic or inherited dyslipidemia, yellowish fatty growths are often present around the 
eyes or the joints. 
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The detection of dyslipidemia usually occurs during rouin lab work or test or after 
CVD event, such as a heart attack or stroke. 
Over time dyslipidemia leads to the formation of plaque on the walls of arteries and 
blood vessels. These plaques reduce size of the vessel openings, creating unstable 
blood flow. As a consequence, increases the work on the heart to pump the blood 
through the constricted regions. 
A blood work, known as a lipid profile, is used to screen for hyperlipidemia. The test 
is done in the fasting state. For men, this type of screening may start as early as the 
age of 20 if they are considered at high risk, and it usual done at a later time for low 
risk men and women. It is advisable to repeat the test every 5 years when the results 
are normal. [9]. 
1.6 Adherence 
Chronic illnesses are frequently treated via the drug therapy treatment for long time. 
While medications are typically successful in treat the disease, often their full benefits 
are not recognized, because around 50% of patients do not adhere to their prescribed 
treatments. The factors that associated with poor adherence vary. For example, these 
include factors related to the patients (e.g., illiteracy and a deficiency in their 
involvement in the treatment plan), factors related to health provider (e.g., complex 
regimens, lack of communication skills, lack information regarding the adverse 
effects, and provision of care by multiple physicians), and health care system related 
factors (e.g., lack of time , access limitation to care, and information technology). 
Impediments to medication adherence are complicated and diverse. Therefore, the 
resolutions to improve adherence need to be multifactorial [10]. 
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Adherence to treatment is commonly defined as the degree to which a patient takes 
the medication as prescribed by their health care provider. For individual patients, the 
rate of adherence is usually reported as a percentage of actual taken medication in a 
specific period of time [11]. 
Patients with acute conditions reported higher adherence rate  relative to those with 
chronic conditions. In fact, adherence for chronic condition patients is unacceptably 
low and drops most radically after 6 months of the therapy [11]. 
Moreover, medication non-adherence affect patients‟ health outcomes range from a 
decreased QoL and poorly managed symptoms to death. However, when examining 
the consequences of medication non-adherence beyond the individual, non-adherence 
is also connected to substantial societal. 
A multidimensional model proposed by the WHO in 2003,  determined by five 
dimensions, including patient-related factors, social and economic factors, the 
healthcare team and system-related factors, and finally the condition and therapy-
related factors [12]. 
Several models describe health behavior based on whether a patient has a positive or 
negative perception of their treatment or health advice.  
For adherence studies, the models include NCF, SRM, and the belief model, which 
suggest that health-related behavior is a rational response that is influenced by 
emotional the patient‟s perception regarding the treatment. Accordingly, the necessity 
concern framework regarding adherence is the outcome of the cut point between a 
patient prescribed drugs and their side effects 
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The Palestinian population, which has reached almost four million, lives in two 
separated areas, namely the West Bank and the Gaza Strip. It is a young population, 
with 46% under the age of 15, and 40% of the population are females who are of 
reproductive age. Despite the young age of this population, chronic disease is a major 
health concern in the occupied Palestinian territory. Specifically, there has been a 
drastic increase in chronic disease, such as cardiovascular disease, diabetes mellitus, 
and dyslipidemia [13]. 
For the past six decades, the political and socio-economic dilemmas of Palestinian life 
have raised important challenges in the health care system with regards to its 
capability to provide adequate services to its population. 
The Palestinian health service provision is inadequate, and at any moment, it is 
subject to sudden discontinuation because of extreme political unrest. Unfortunately, 
the health service provision does not have an alternate plan to address the people's 
needs efficiently in such a situation [13]. 
 
 
Palestinians are affected by the perplexing living conditions and the socio-cultural 
norms and attitudes that affect their well-being and quality of life. Ultimately, for 
patients, all of these factors contribute to medication adherence. [14]. 
 
The patient's beliefs and attitudes  as related to their hyperlipidemia  medications 
influence their adherence. The usage and acceptance of these medications by the 
patients is critical. This study aims to fill the gaps between patients‟ knowledge and 
adherence.  
9 
 
 
1.7  High probability factors affecting patient adherence to 
medication  are shown as in the diagram [15]  
 
 
Figure 1.1: Five dimensions of adherence.    
 
1.8  Prevalence of dyslipidemia 
A study conducted by The National Health and Nutrition Examination Survey 
(NHANES), between 1999 and 2002, revealed that the estimated prevalence of 
dyslipidemia was 52.9% [16]. 
 
Using the updated NCEPATP III criteria, the Multi-Ethnic Study of Atherosclerosis 
(MESA) study, which was conducted in six American communities between 2000 and 
2002, demonstrated that the overall prevalence of dyslipidemia was 29.3% [17]. 
 
 
 
 
Social 
economic 
Condition 
related 
Therapy 
related 
Patient 
related  
Health care 
system 
Five dimensions 
of adherence    
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Dyslipidemia in the Middle East:  
 
The prevalence of dyslipidemia in the Middle East has been examined is several 
studies.  
However, in most of them the assessment of the prevalence of dyslipidemia centered 
on the updated NCEP ATP III, and different cut-off values and lipid level ratios were 
used [18]. 
 
Moltagh and colleagues reported, in a systematic review, that based on risk factors 
related to the CVD in the Middle East from between the period January 1980 to April 
2005, the prevalence of dyslipidemia could not be calculated because of noticeable 
disparities in the definitions used in the different studies [19] . 
Additionally, the systematic review conducted in gulf countries by Aljefree and 
colleagues examined the CVD risk factors in adult populations from 1990 to 2014 and 
revealed that the prevalence of hypercholesterolemia ranged from 17% to 54·9% in 
males and 9% to 53·2% in females [20]. 
 
Dyslipidemia in Palestine: 
 
In 2018, the number of deaths in Palestine reached 12,098 in the West Bank and 4,950 
in the Gaza Strip, which was 59.1% and 40.9% of the total deaths, respectively. 
The primary cause of death in Palestine in 2018 was cardiovascular diseases, 
accounting for 31.5% of total reported deaths. [21] 
According to the annual report for the UNRWA about medical expenditures, the total 
in 2018 was US $12.1 million.[21] 
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An analysis of the expenditures on different medicines revealed that 43.0% of the 
funds were spent on medicines used to treat NCDs, 5.0% were cardiovascular 
medications, and 8.4% were lipid lowering agents. [21] 
Since dyslipidemia is one of the most prominent causes of cardiovascular disease, it is 
necessary to examine the reasons that prevent patients from continuing to take their 
medication. 
 
1.9 Problem statement: 
There are many factors that may pose challenges and affect a patient‟s adherence to 
his/her medication such as the following: 
Multiple medications may be taken by a patient to treat other diseases, which may 
have an effect on the adherence of patient to his/her dyslipidemia medications; the 
cost of the medication; the length of the treatment period, which lowers patient 
adherence to medication; and the patient's misconception that prolonged use of the 
drug will cause serious side effects. 
1.10  General Objectives : 
To identify the predictors of dyslipidemia medication adherence which 
will help to improve patient adherence and enhance awareness about 
importance of dyslipidemia medications in patient with high risk of CAD. 
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1.11  Specific objectives:  
1- To measure patient beliefs about high cholesterol and cholesterol lowering 
medication. 
 
2- To assess patient adherence to taking dyslipidemia medications. 
 
3- To find a relationship between adherence and beliefs. 
 
4- To find a relationship between adherence, beliefs, and other demographic and 
clinical data.  
 
The present study evaluated medication adherence among dyslipidemic  patients using 
the four-item Morisky Medication Adherence Scale (Appendix C ). It additionally 
investigated patient beliefs concerning medicines using the Beliefs about Medicines 
Questionnaire (Appendix A), and explored the relationships of these beliefs and other 
demographic and clinical variables with medication adherence. 
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Chapter Two 
ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
Literature review 
2.1 Literature review:  
Drugs cannot be effective if patients do not take them in the first place. Many studies 
have been conducted to evaluate medication adherence and performance. One such 
study evaluated the Portuguese versions of the Morisky-Green test and the Brief 
Medication Questionnaire (BMQ) in terms of reliability and performance in the 
context of patients receiving hypertensive treatment at a primary healthcare unit in 
Brazil by Vasan .[22] another study was done by Kuller found that BMQ to perform 
better in terms of both sensitivity and specificity. Effective evaluation of patient 
adherence is important as a means of helping clinicians to differentiate insufficient 
treatment regimens from the inadequate use of medication [23, 24].  
In observational studies, low adherence to hypertensive treatment has been considered 
a barrier to control of blood pressure [25].  
However, opinions vary as to what degree of adherence is adequate; some trials 
consider 80% or more to be acceptable, while others consider 95% to be the target 
minimum, especially when the treatment is for a serious condition such as the human 
immunodeficiency virus. Many factors affect the pattern of adherence to a medication 
regimen, such as patient beliefs; for example, a 2013 study by Berglund concerning 
adherence to statin treatment highlighted the importance of patient beliefs about 
14 
 
medications, their experience of cardiovascular events, disease burden, and the degree 
of perceived control [26]. Patients with a high perception of treatment necessity 
generally adhered to their regimen well, while side effects were shown to negatively 
impact adherence. 
 The study was done by Haynes and Mamdani  in 2002 show that Although adherence 
is frequently reported as a binary variable (adherence vs. non-adherence), it is most 
precisely represented by a continuum ranging from 0 to more than 100 percent, which 
accounts for the possibility of patients taking more medication than they are 
prescribed. For individual patients, rate of adherence is most often reported as the 
percentage of prescribed doses that are actually taken over a given interval. This 
definition has been further refined by some investigators to separately consider dose 
taking (number of pills per day) and dose timing (taking pills within a given period). 
Higher adherence is typically observed for patients with acute conditions; in those 
with chronic conditions, adherence is unfortunately low, with a substantial drop 
occurring six months after the initiation of therapy [27, 28]. In addition, physician 
ability to recognize non-adherence is frequently poor, and interventions with the goal 
of increasing adherence have yielded mixed results [29, 30]. In spite of all efforts to 
date, a broad gap remains between evidence-based guidelines and actual primary care 
practice. This gap is predominantly ascribed to failures of physician and patient 
adherence, and studies that evaluate adherence are essential for helping to narrow it. 
Studies that evaluate beliefs and adherence are important because in spite of all efforts 
a wide therapeutic gap still exists between evidence-based guidelines and their 
practice in the primary care, which is primarily attributed to physician and patient 
adherence. 
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One study done by Qneibi in Palestine indicated that failure to follow guidelines 
could largely be ascribed to non-adherence by physicians [31]. It additionally 
identified the most challenging issue to be pharmacotherapy initiation, and that 
greater adherence mainly occurred in conditions of high volume with respect to 
patients and visits. The practical implications noted by the authors were a need for 
more frequent follow-up visits and greater focus in primary care on the prevention of 
metabolic conditions by cardiologists or by primary care clinics specializing in 
metabolic conditions. 
Another study conducted by Goff  in England showed that approximately 20%-50% 
of patients do not take medication as prescribed, which may have related to fear of 
interactions between medications, adverse effects, misunderstanding of the necessity 
of medication, a perceived lack of effectiveness, or concern regarding cost [32]. This 
study also suggested there may be modifiable entities that influence medication 
adherence, including participant concerns about the relationships of doctors and 
pharmaceutical representatives and their beliefs regarding the best medications for 
their conditions. One of the most important points highlighted by this study is the 
patient-doctor relationship as a factor in both belief and preference; that is, trust 
between doctor and patient is necessary for a medication recommendation to be 
accepted 
A pilot study carried out at Georgia by Robinson evaluated the relationship of beliefs 
to adherence in a rural population, specifically concerning high cholesterol and 
cholesterol-lowering medication. Adherence was assessed using the Morisky scale, 
and beliefs about medication with the HABIT questionnaire [10]. 
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A study conducted by Sweileh in Nablus investigated medication adherence, beliefs 
concerning medications, and the influence of beliefs on adherence in Palestinian 
patients with chronic illness. The results demonstrated that patient beliefs contribute 
substantially to medication adherence [33]. 
Finally, another study conducted by Qadah  measured the relationship between self-
reported belief and adherence of hypercholesterolemia patients at a single clinic in 
Nablus. The authors concluded that beliefs and adherence correlate significantly with 
the achievement of target LDL-C values[34]. 
 
2.2 Significance of study : 
As mentioned previously, there is a clear problem with adherence to chronic 
medications. Dyslipidemia is a condition that requires continuous administration of 
medications for disease control. Furthermore, some of these medications have serious 
side effects such as myopathy and rhabdomyolysis. This study will evaluate patient 
beliefs about lipid-lowering medications in the middle area of the West Bank, 
specifically the cities of Ramallah and Bethlehem. Furthermore, patient adherence to 
medications will be measured and their sociodemographic characteristics recorded. 
The key contribution of this study is the identification of factors that predict 
adherence to dyslipidemia medication, which will help to improve patient adherence 
and enhance awareness of the importance of dyslipidemia medications in patients 
with a high risk of CAD. 
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Chapter Three 
ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
Methods and Materials 
3.1 Study design 
This study, conducted between January and July 2019 in a Palestinian population, 
used a cross-sectional design to evaluate the influence of patient demographic 
characteristics, patient beliefs about medications, and clinical factors on adherence to 
treatment with cholesterol-lowering medications.  
3.2  Study setting 
This study was conducted at two middle governmental primary healthcare clinics in 
the cities of Ramallah and Bethlehem. Both centers provide care for patients with 
chronic illnesses, including: diabetes mellitus, hypertension, hyperlipidemia, heart 
failure, psychiatric conditions, and respiratory diseases.  
3.3 Study Participants  
Participants were selected from patients who are provided with medical care and anti-
hyperlipidemia medications at the selected healthcare centers with regular follow-up. 
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3.4 Sampling procedure and sample size calculation 
This cross-sectional survey used the Morisky Medication Adherence Scale (MMAS-
4) and the Beliefs about Medicine questionnaires. The necessary sample size was 
estimated using Raosoft (http://www.raosoft.com/samplesize.html), which determined 
170 patients across both clinics to be required for adequate power. Participants were 
recruited by means of convenience sampling. 
3.5 Inclusion and exclusion criteria 
 
The following criteria were required for participant inclusion: age at least 18 years, 
able to read or understand Arabic, willing to take part in the study, hyperlipidemia 
diagnosis at least one year prior, currently being treated for hyperlipidemia, and  LDL 
and TC levels available retrospectively from medical records within six months of 
study participation. 
 Participants were excluded if their anti-hyperlipidemia medication had been taken for 
less than one year or if diagnosed with a mental or severe cerebral vascular disease 
potentially affecting their cognitive ability. 
3.6 Instruments and data collection form 
The questions in this cross-sectional, questionnaire-based study (see Appendix A) 
were adapted from three different published questionnaires. The survey used 
contained four sections: 
Section One:  Demographic Variables 
The first part of the questionnaire addressed socio-demographic factors such as age, 
gender (male, female), marital status, education level (elementary, preparatory, 
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secondary, higher education), residency (city, village, or Palestinian refugee camp), 
employment, and primary health care center. 
Section Two: Medication adherence   
Self-reported medication adherence was measured using the four-item Morisky 
Medication Adherence Scale (MMAS-4) (Morisky, Ang, Krousel‐ Wood, & Ward, 
2008) (Morisky, Green, & Levine, 1986), in which all questions had dichotomous 
responses (No=0 and Yes=1). Total scores were summed (range 0-4), with scores of 
0-1 denoting high adherence and 2-4 denoting low adherence. 
The MMAS is perhaps the most widely-accepted instrument for measuring self-
reported medication adherence, and has been confirmed in patients with other chronic 
diseases as having outstanding validity and reliability. 
Section Three :Beliefs about medications  
Beliefs about medicines were collecting using the Beliefs about Medicines 
Questionnaire (BMQ) developed by Horne et al. (Horne, Weinman, & Hankins, 
1999). The Arabic version used in this study was validated in 2012 for use in patients 
with chronic illness (Alhalaiqa, Deane, Nawafleh, Clark, & Gray, 2012).  The BMQ 
consists of two five-item scales, one of which assesses perceived necessity of a 
prescribed medication for controlling the patient‟s illness and the other their concerns 
about the medication‟s potential adverse consequences. 
The necessity scale consists of items such as: “My health, at present, depends on my 
medicines” and “My medicines protect me from becoming worse.” The concerns 
scale consists of items such as: “I sometimes worry about the long term effects of my 
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medicines” and “I sometimes worry about becoming too dependent on my 
medicines.”  
On either scale, each item is scored from 5 (strongly agree) to 1 (strongly disagree), 
with a higher score representing stronger belief or concern; summing along a scale 
gives a total score ranging from 5 to 25. Subtracting concern from necessity gives the 
necessity-concerns differential score (-20 to 20), for which a positive value indicates 
that the patient perceives medication benefits to outweigh risks, and a negative value 
the inverse. Furthermore, patients were categorized into four attitudinal profiles by 
dividing the scales at their midpoints (i.e. 15): “indifferent” (low necessity, low 
concern), “skeptical” (low necessity, high concern), “accepting” (high necessity, low 
concern), and “ambivalent” (high necessity, high concern). 
 Section Four : Clinical Variables 
This part of the questionnaire pertained to clinical variables, namely: LDL, TC, 
duration of hyperlipidemia, the presence of co-morbid conditions, and the medications 
used to control LDL with their dosages and treatment duration.  
3.7 Ethical approval 
Before the initiation of this study, all aspects of the protocol were authorized by the 
Al-Quds University Institutional Review Board and local health authorities at the 
study sites.  This includes. 
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3.8 Pilot study 
A pilot study (25 participants) was carried out to test the survey tool, ensure the 
necessary data would be available, estimate the required time, and identify any 
modifications needed in the data collection form. Patients who participated in the pilot 
study were excluded from the final analysis,we found it is suitable with no change 
were made with questionnaire.   
3.9  Statistical analysis 
All analyses were carried out using the Statistical Package for Social Sciences 
(SPSS), version 21. Continuous variables (e.g. age, number of medications) were 
expressed as mean ± SD, and categorical variables as frequencies (percentages). The 
normality of each variable was evaluated using the Kolmogorov-Smirnov test. For 
categorical variables, significance was tested using either chi-square or Fisher‟s exact 
test, and differences in category means by Kruskal-Wallis or Mann-Whitney test. For 
all analyses, results were considered significant if the obtained p-value was less than 
0.05. 
 
 
 
 
 
 
 
22 
 
 
Chapter Four  
ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ 
Results 
4.1. Patient characteristics   
Of the 220 patients approached for this study, a total of 185 agreed to take part 
(response rate 84.1%). Of responders, 106 (57.3%) were men. Almost half of the 
participants (88, 46.5%) were ≥56 years of age; 79.7% had been widowed; 42.7% 
were not educated; and 64.1% described themselves as religious. Two-thirds of 
participants (65.4%) reported school education, while only 22.2% were educated at 
the college or university level. Also, 119 (64.32%) had been prescribed with more 
than four drugs. Nearly all patients were taking statins (168, 90.80%) and had done so 
for an average duration of 8.6 ± 4.7 years; the mean total cholesterol of participants 
was 263.1±52.1 mg/dl. Participant characteristics are detailed in Table 2.  
4.2 Non-adherence behaviors  
In this study population, medication non-adherence as captured by Morisky 
medication adherence scale four item was high (47.6%). Univariate analysis revealed 
that non-adherence was most likely among illiterate patients (P=0.03), those on more 
than four drugs (P<0.001), and those having comorbidities (P<0.001) (Table 2).  
Non-adherence was most commonly attributed to forgetfulness (35.2%), and second-
most to insufficient care about taking medications (27.3%). Non-adherence was 
commonly unintentional (70.5%), and less often either intentional (26.1%) or mixed 
in intent (20.5%) (Table 3). 
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Table 4.2 Patient characteristics and univariate analysis results reflecting potential 
contributions of characteristics to medication adherence. 
                                                              
Variable n (%) All 
patients  
     (185) 
High 
adherence 
     (97) 
Low 
adherence 
    (88) 
P-
value  
Gender      
     Male   106  (57.3)  55 (56.7)  51 (57.9) 0.61
¥
 
     Female     79 (42.7) 42 (43.3) 37 (42.04)  
Age      
     18-35 years   22 (11.9)   9 (9.3) 13 (14.8) 0.11
¥
 
     36-55 years  77 (41.6) 35 (36.1) 42 (47.7)  
     ≥ 56 years   86 (46.5) 41 (42.3) 45 (51.1)  
Education Level      
      Illiterate   23 (12.4)   8 (8.24) 15 (17.04) 0.03
¥
 
      School level 121 (65.4) 66 (68.04) 57 (64.8)  
      College/university level   41 (22.2)  29 (29.89) 16 (18.2)  
Living Status      
     Living Alone   19 (10.27) 7 (7.22) 12 (13.64) 0.06
¥
 
     Living with Someone 166 (89.73) 90 (92.78) 76 (86.36)  
 BMI     
       Normal   66 (35.68) 38 (39.28) 28 (31.82) 0.45
¥
 
       Overweight   89 (48.12) 48 (49.5) 44 (50.0)  
       Obese   30 (16.22) 11 (11.34) 19 (21.59)  
     
 Polypharmacy     
       <4   119 
(64.32) 
69 (71.13) 50 (56.82) <0.001
¥
 
       >4     66 
(35.68) 
28 (28.87) 38 (43.18)  
 Comorbidities     
       Yes 125 (67.57) 55 (56.70) 70 (79.54)   
        No 60 (32.43)   42 
(43.29) 
18 (20.45) <0.001
¥
 
     
Medications      
Statins 168 (90.80) 90 (92.8) 78 (88.6) 0.55 
Fibrates 15 (8.21) 7 (7.2) 8 (9.0)  
Others 2 (1.1) 0 2 (2.4)  
     
 Duration of statin use (years±SD)       8.6 ± 4.7  7.3± 4.1 8.8± 4.4 0.06
*
 
          
Total Cholesterol (mg/dl±SD )   263.1 ± 256.8 ± 269.9 ± 0.07
*
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52.1 50.5 53.2 
LDL-C (mg/dl±SD)   140.0 
±18.1 
140.6 ± 
18.3 
137.7 ± 
17.9 
0.63
*
 
HDL-C (mg/dl±SD)   53.2 ± 6 54.1 ± 6.6 53.1 ± 5.4 0.71
*
 
Total Morisky score (±SD)   1.4 ± 0.5 0.961 ± 
0.17 
2.0 ± 0.3 <0.00
*
 
¥ = Chi square test for categorical groups. * = T-Student Test. LDL = Low density lipoprotein, HDL = High 
density lipoprotein. Total Morisky score range 1-4. 
 
 
 
 
Table 4.3. Adherence and non-adherence among study participants (n= 185). 
 
Prevalence of Adherence/Non-
Adherence  
Total 185 (%) 
Adherent Patients 97 (52.4) 
Non-Adherent Patients 88 (47.6) 
Likely cause of non-adherence  Total 88 (%)  
Forgetting to take medication 31 (35.2) 
Careless at times about taking medications  24 (27.3) 
Feeling better  17 (19.3) 
Feeling worse  13 (14.7) 
Type of Non-Adherence Behavior  Total 88 (%) 
Unintentional  62 (70.5) 
Intentional  23 (26.1) 
Mixed  18 (20.5) 
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4.3 Beliefs concerning medicines  
Among participants in this study, a majority (65.5%) reported a positive belief in the 
necessity of their current treatment to maintain good health (i.e. not become ill). 
Hyperlipidemia treatment was additionally regarded by most (52.7%) as important for 
ensuring future health (Figure 2). 
 
Fig. 4.2 Respondent agreement (agree/strongly agree) with questionnaire statements 
(necessity-statements). 
However, despite these beliefs, 60.1% of participants also reported concerns about 
their dyslipidemia medications having long-term or adverse effects. Overall, most 
participants (54%) were concerned about becoming dependent upon anti-dyslipidemic  
agents. There was much less concern about the medications disturbing their lives 
(Figure 3). Notably, the mean concern score of 13.21(S.D. 3.2) was significantly 
below the mean necessity score of 17.92 (S.D. 3.2; P<0.001), for a mean necessity–
concern differential of 4.7 (S.D.1.4). However, individual necessity scores were lower 
65.5% 
61.2% 
52.7% 
49.3% 
42.6% 
0.0% 20.0% 40.0% 60.0% 80.0%
Without my medicines I would become very ill
My medicines protect me from becoming worse
My health in the future will depend on my
medicines
My health at present , depends on my medicines
My life would be impossible without my
medicines
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(i.e. necessity–concerns differentials were negative) for 33 participants (17.8%), while 
equal scores were obtained for eight participants (4.3%).  
 
Fig. 4.3 Respondent agreement (agree/strongly agree) with questionnaire statements 
(concern-statements). 
 
To group participants, their beliefs were categorized as high or low relative to the 
scale midpoints (Specific-Necessity and Specific-Concerns), defining four attitudinal 
categories: Accepting high necessity, low concern  (93, 50.3%), Ambivalent high 
necessity, high concern  (48, 25.9%), Skeptical high concern, low necessity (19, 
10.3%), and Indifferent low concern, low necessity (25, 13.5%) (Fig. 4).  
Chi square analysis showed significant variation in non-adherence across attitudinal 
groups, χ2 (3, n=185) =13.47, P=0.004. A majority (60.8%) of adherent patients were 
accepting, compared with 38.6% of the non-adherent group. In contrast, 78.9% of 
non-adherent patients were skeptical, compared with 21.1% of the adherent group.  
 
60.1% 
54.1% 
48.4% 
24.4% 
21.7% 
0.0% 20.0% 40.0% 60.0% 80.0%
I sometimes worry about the long term
effects of my medicines
I some worry about becoming too
dependent on my medicines
Having to take medicines worries me
My medicines disrupt my life
My medicines are a mystery to me
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Fig. 4.4 Classification groups describing patient attitudes toward their medications. 
   
4.4 Association of beliefs with other factors 
Analysis revealed that adherent patients more strongly believed they had personal 
need of anti-dyslipidemia drugs. Meanwhile, non-adherent participants possessed 
stronger concerns about long-term use of medications and potential adverse events in 
the future (Table 4). The Necessity-Concerns Differential (NCD) score of non-
adherent participants was lower than that of adherent participants (4.7 vs. 1.7, 
P<0.001), revealing that for non-adherent participants, belief in the need for anti-
dyslipidemia agents was similar to concern about long-term use of the medications.  
 
High 
Concerns  
Low 
Concerns  
Low 
Necessity  
High 
Necessity  
Ambivalent 
48 (25.9%) 
 
Skeptical  
19 (10.3%) 
 
Indifferent 
25 (13.5%) 
 
Accepting 
93 (50.3%) 
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Table 4.4 Necessity and concern scores for adherent and non-adherent patients.  
Score  Adherent  
Mean (sd) 
Non-adherent  
Mean (sd) 
t (df) Mean 
difference  
CI, 95% P-value  
Necessity 
score  
17.92 (3.2) 16.63 (4.1) 2.4 (185) 1.29 0.23-2.3 0.018 
Concerns 
score  
13.21 (3.2) 14.91 (3.7) -3.3(185) -1.69 -2.70- -0.68 0.001 
NCD  4.7 (1.4) 1.7 (0.16) 3.5 (185) 2.96 1.33-4.54 0.001 
NCD =Necessity-Concerns Differential, sd = standard deviation, df=degrees of 
freedom  
 
Table 5 gives additional results correlating necessity scores with patient 
characteristics. The mean necessity score for men was not significantly greater than 
that of women (17.7 vs. 16.8, P=0.14). However, a significant negative correlation 
was observed when considering total cholesterol (P=0.03) or Morisky score (P=0.01). 
No significant association was identified that connected any other demographic or 
clinical variables with necessity scores.   
Table 4.5 Association of participant characteristics with necessity scores.  
Variables  N Pearson’s 
correlation  
P-value  
Age (years, SD) 185 0.059 0.49 
Duration of statin use (years) 185 0.042 0.61 
Number of medications taken 185 -0.144 0.09 
Total cholesterol (mg/dl) 185 -0.21 0.03 
LDL-C (mg/dl) 185 0.11 0.13 
Mean Morisky adherence score  185 -0.38 0.01 
 
Unlike necessity scores, concern scores were found to have significant associations 
with demographic and clinical variables (Table 6). Namely, significant positive 
correlations were identified with the number of medications being taken (P=0.01) and 
Morisky score (P=0.01). No significant correlations were identified for other 
demographic or clinical variables. 
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Table 4.6 Association of participant characteristics with concern scores. 
Variables  N Pearson’s 
correlation  
P-value  
Age (years, SD) 185 0.03 0.69 
Duration of statin use (years) 185 0.12 0.18 
Number of medications taken 185 0.33 0.01 
Total cholesterol (mg/dl) 185 0.34 0.01 
LDL-C (mg/dl) 185 0.067 0.44 
Mean Morisky adherence score  185 0.43 0.01 
 
Associations of independent variables with low adherence were predicted using a 
stepwise multivariate logistic regression model (Table 7). Four variables were 
identified as remaining significant and associated with non-adherence: illiterate 
(OR=2.52; CI: 0.9–4.3), polypharmacy (OR=3.18; CI: 1.9-5.7), having a comorbidity 
(OR=3.10; CI: 2.2-4.6), and having concerns about side effects (OR=2.89; CI: 1.1-
4.6).  
 
Table 4.7 Multiple regression analysis for variables predicting non-adherence.  
 Β OR CI  P-Value 
Education (illiterate) 0.924 2.52 0.9-4.3 0.032 
Living alone 0.285 1.33 0.5-2.7 0.157 
Polypharmacy >4 1.157 3.18 1.9-5.7 0.007 
Duration of statin use >5 years 0.599 1.44 1.3-3.3 0.093 
Having comorbidity  1.410 3.10 2.2-4.6 0.005 
Having concerns about side effects  1.06 2.89 1.1-4.4 0.043 
Necessity score <15 0.322 1.38 0.6-3.3 0.113 
β, regression coefficient.; OR, odds ratio; CI, confidence interval 
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Chapter five 
ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
Discussion 
 
For this analysis, patients were only considered adherent if scored as high adherence 
(score of 0-1); those who scored >1 were considered to have low adherence. More 
than 90% of participants were taking statins, and 47.6% self-reported low adherence. 
Our findings are inconsistent with previous studies, which determined that 33% to 
50% of patients stop taking statin medication one year after treatment and that 
adherence decreases over time [39]. The most likely causes of low adherence in our 
sample were unintentional forgetfulness and carelessness in taking medications, 
which were reported by 35.2% and 27.3% of patients, respectively. However, nearly a 
fifth of patients (19.3%) reported intentional non-adherence in that they stopped 
taking their medications upon feeling better. The overall non-adherence rate (46.7%) 
in this study concurs with prior reports by Elsous et al. (52.3%) [40], Jackson et al. 
(51.2%) [41], and Bizu et al. (51%) [42]. However, lower adherence rates have also 
been reported by Sweileh et al [43]. and Jamous et al. [44], at 16.9% and 42.7%, 
respectively.  
In this study population, non-adherence was primarily caused by unintentional 
behaviors, most commonly forgetfulness and carelessness about medication time [45]. 
Reasonable explanations for these behaviors may be attributed to multiple factors, 
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including work, travelling, economic status, and lack of effectiveness or adverse 
effects of the medications [46]. 
The main finding concerning beliefs about medicines was that the majority of patients 
having hyperlipidemia hold positive beliefs with regard to medication necessity (mean 
necessity score 17.3). However, a high proportion of participants also expressed 
concerns about long-term and potential adverse effects. Bruckert et al. [47] reported 
that among patients with hyperlipidemia who were treated with high-dose statins, 
10% experienced myopathy; among those, nearly a fifth discontinued treatment 
(19.8%), and a similar percentage had their dosages reduced (16.7%). A recent review 
by Fernandez et al. [48] additionally showed that up to 20% of patients receiving 
statins experience myopathy.  The importance of patient perception of side effects in 
adherence has been demonstrated by several studies [49],[50], and non-adherence 
may be particularly likely for patients on high doses of cholesterol-lowering drugs 
who experience adverse events [51]. 
In this study, no association was identified connecting necessity score with the 
demographic variables of age, duration of hyperlipidemia, or the number of drugs 
being taken. However, necessity scores were negatively associated with mean 
Morisky medication adherence (low score meaning higher adherence) and with total 
blood cholesterol level. This finding is reasonable as better adherence with lipid-
lowering agents will result in a decrease of total cholesterol in the blood. Meanwhile, 
significant and positive associations with concern scores were observed for Morisky 
score, high blood cholesterol level, and number of medications taken. These findings 
are in line with prior reports in US specialist care and in the context of various long-
term conditions [15]. 
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Patient adherence was further evaluated in terms of attitude by combining necessity 
and concern ratings in a two-dimensional analysis. Most participants (50.3%) 
classified as accepting of their anti-hyperlipidemic agents (high necessity, low 
concern). Participants who classified as skeptical (high concern, low necessity) were 
more likely to also have low adherence.  
Logistic regression revealed several factors predictive of non-adherence behaviors; 
illiteracy and low education (at most through primary school) were the most likely 
predictors (P=0.03). Many previous studies have similarly reported higher rates of 
non-adherence among patients of lower education levels [52],[53] . Lower education 
is also associated with lower socioeconomic status, poor access to the health system, 
and less knowledge about their disorder [54]. Thus, providing more accessible 
facilities and arranging educational and training programmes can improve treatment 
adherence [55]. 
Polypharmacy (having more than four drugs prescribed) was found to be highly 
predictive of non-adherence (P=0.007). A recent review study by Zelko et al. [56] 
found that for polypharmacy patients, non-adherence rates ranged from 6% to 55%. 
Other studies have also reported negative associations of medication adherence with 
more drugs being taken, a large caregiver burden, and also impaired hearing and poor 
cognition  [57],[58]. In the present study, comorbidity was another highly significant 
predictor of non-adherence (P=0.005). This finding is consistent with other studies in 
the literature, which have reported association of comorbidities with depression, 
anxiety, and stress, which then have negative effects on adherence [59],[60]. 
  The last independent predictor of non-adherence identified in this analysis was 
concern about medications (P=0.04), consistent with prior literature [61],[62]. 
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Consideration of patient concerns may be essential in ensuring adherence and 
effective use of medication; patient concerns have been found to predict non-
adherence in terms of both extent and direction (over- or underuse) [63]. 
When developing interventions to improve adherence, the aim should be to address 
modifiable factors, and  the patients targeted should be those most likely to not 
adhere. However, the currently available literature on adherence is highly 
heterogeneous; efforts are first needed to improve the standardization and therefore 
comparability of adherence studies.  
Patient education and information has been shown to lead to enhanced knowledge and 
improved lipid-control behaviors [64]. A systematic review of seven studies involving 
educational and knowledge interventions [65] found that participants who received an 
intervention were more adherent than those who received only usual care (odds ratio  
1.93, 95% confidence interval 1.29-2.88). 
The results of this work indicate that patients with risk factors pay more attention. 
Accordingly, patient beliefs about the risks of high cholesterol and the severity of 
high cholesterol are significantly associated with medication compliance, and 
adherence then reinforces the beliefs. Other studies have reported that patient beliefs 
about the importance of cholesterol in heart disease incidence will increase patient 
motivation for adherence to medication [66]. Meanwhile, patients who lack 
understanding of the risks associated with high cholesterol may be less likely to 
believe the condition is serious and that aggressive treatment is necessary [67]. 
Pharmacists are in an ideal position to enhance adherence among hyperlipidemic 
patients. A number of interventions that involve pharmacists have been documented 
in the literature, including counselling visits at the pharmacy [67], making phone calls 
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[68] and leaving voice messages [69], telephone counselling coordinated by a 
computer-based tracking system [70], and preparing a „beepcard‟ to provide 
reminders when a dose is due [71]. 
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Chapter Six 
ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
Conclusion 
6.1 Strength of our study: 
Major strength of this study include: this is the first study about beliefs of cholesterol 
lowering drug and medication adherence among Palestinian adult with dyslipidemia 
conducted at west bank in Ramallah and Bethlehem . 
It provides baseline data about Palestinian dyslipidemic patients adherence to their 
medication, their mostly commonly used medication ,also tried to identify significant 
factors that may pose challenges and affect patients adherence to his /her medication. 
This study is the first of its type in Palestine and Arab world that classified patients 
attitudes toward their medications as four attitudinal categories :accepting (high 
necessity /low concern), ambivalent (high concern /high necessity), skeptical (high 
concern / low necessity), 
Indifferent (low concern/low necessity). 
Only few studies examined the beliefs and adherence of dyslipidemia patients to their 
medication .also ,the current study measured both beliefs and adherence to medication 
among dyslipidemia patients by using the global instruments: MMAS-4, BMQ scales. 
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6.2 Recommendation and limitations  
Surveys and self-reported methods have potential limitations, which are prone to 
recall biases and /or overestimation of adherence rate may have occurred. Due to the 
nature of the study as a questionnaire-based study, explaining the cause and effect of 
non-adherence is limited. Finally, the study covered only two medical center, which 
may have to some extent limited the overall generalizability of the findings. 
Moreover, cross-sectional study cannot permit drawing causal associations between 
the factors studied and results should be confirmed in prospective follow-up studies. 
This study could carry important recommendations for health centers in terms of 
providing health education and awareness of patients and devote more time to follow 
the doctor to the patient's condition, as it should. It highlights the importance and 
prognostic value for the patient's continued taking of his medicine and his 
commitment throughout the diagnosis, prognosis and treatment period.  
 
Trying to provide the medicine permanently to patients in health centers that it needs 
permanent and uninterrupted treatment for these medicines. 
 
Based on the results from our study, we can give an objective proof for predictors of 
dyslipidemia medication adherence which will help to improve patient adherence and 
enhance awareness about importance of dyslipidemia in patient with high risk of 
CAD. 
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6.3 Conclusion  
This study contributes to the increasing evidence suggesting that patient concerns and 
beliefs about medication are associated with adherence behavior. In addition, 
direction of non-adherence was related to specific types of concern. Patient concerns, 
long-term effect and experiencing side effects appear more pivotal in determining 
non-adherence than both level of LDL and cholesterol. 
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Appendices A: 
 
 
 
 
 
 
Evaluation of adherence of patients with cholesterol-lowering drugs to their 
prescribed treatment and their impact on drug conviction in the Bethlehem and 
Ramallah areas of the West Bank at the Palestinian Ministry of Health. 
 
I would like to require from you to participate  in a research entitled Evaluation of the 
commitment of a patient to reduce cholesterol by his medication based on his belief 
and belief in the effectiveness of the treatment given to him.  
 
 
The researcher is a master's student in the Faculty of Pharmacy, Al-Quds University. 
 The aim of the study is to evaluate the patient's responsiveness and commitment to 
his medications and to see the relationship between the patient's convictions and their 
impact on his commitment to treatment. 
 
 
Your participation in this research is voluntary and can be rejected. You can also 
leave an answer to any question you do not wish to answer. 
 
44 
 
Your identity will remain anonymous and the data obtained will only be used for 
scientific research purposes and will be kept confidential. 
If you agree to participate, please answer the questions carefully and objectively 
 
Thanks for your cooperation 
Researcher 
Jihad Shakarna. 
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Section one :    personal information 
 Age (year) 
61 ≤  (56-60) (41-55) ≤40 Age  
 Female  Male  Sex  
 Ramallah  Bethlehem  Address  
 Yes  No  Job  
High education  Secondary  Preparatory  Elementary  Education  
≥2000 (1500-2000) (1000-1500) ≤1000 Income 
Widowed  Divorce  Married  Single  Status  
 
 
Section two: Patient response and commitment to medicine based on Morisky 
fourth scale   
2-No 1-Yes 1-do you ever 
forget to take 
medication? 
2-No 1-Yes 2- Are you carless at times 
about  taking your 
medication? 
2-No 1-Yes 3-When you feel better, do 
you sometimes stop taking 
your medication ?  
2-No 1-Yes Sometimes ,if you feel 
worse when take your 
medicine, do you stop 
taking it?  
 
Section three( part one ):patients  beliefs toward illness and medication  
5- Strongly 
agree 
4-Agree 3-
Indifferent  
2-
Disagree 
1-Strongly 
disagree   
     
My current 
health 
status 
depends on 
my 
medication. 
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My life will 
be 
impossible 
without 
taking my 
medicine. 
 
     
Without my 
medication 
I will 
become 
very ill. 
 
     
My future 
health 
depends on 
taking my 
medication. 
 
     
My 
medications 
protect me 
from 
becoming 
worse. 
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Section three (part two): patient concerns about medication 
5- Strongly 
agree 
4-Agree 3-Indifferent 2-Disagree 1-Strongly 
disagree 
 
     
The need to take medicine 
worries me. 
 
     I sometimes feel worried 
about the long-term effects 
of my medication. 
 
     My medication is puzzle 
for me . 
     My medication is 
disrupting my life. 
 
     
Sometimes ,I  was worried 
that I became too 
dependent on my 
medication  
 
 
 
 
 
 
 
48 
 
 
 
 
 
 
 
 
 
 
 
 
Section Four:  Questions related to dyslipidemic patient about their disease and 
treatment  (Medical History). 
 ≥10 year   (6-10)year (1-5) year  year ≥ Duration of disease 
(year) 
   2………
…………. 
1-
…………………
………. 
If you are using lipid 
lowering drug 
,please mention? 
5- 
no  
4- other 
disease  
3-diabetes  2-CVD 1-hypertension Other disease? 
   2-No 1-Yes   Does a member of 
your family suffer 
from cardiovascular 
disease? 
 
  3- leave 
smoking 
since……… 
2-No 1-Yes, 
duration
………
…. 
Smoking ? 
   2-No 1-Yes Physical activity ? 
≥9
0c
m 
81-90cm 71-80cm 61-70cm 50-60cm Waist circumference 
  150 kg≤ 2- (101-
150)kg 
1-(50-100)kg Weight  
 94
 
 
 B  secidneppA
 
 
 
 
حمييُ اٌخضاَ ِشضى أدٚيت خفض اٌىٌٛيسخشٚي بعلاجُٙ اٌّٛصٛف ٚحأثشٖ بالخٕاعُٙ باٌذٚاء  في ِٕاطك بيج 
  في اٌضفت اٌغشبيت  في ٚصاسة اٌصحت اٌفٍسطيٕيت ٚساَ اللهٌحُ 
 
 حعشح اىسٞذ/ اىسٞذح اىَشبسك ثبىجحش
اىن٘ىٞسزشٗه ثذٗائٔ ثْبء عيٚ اسع٘ ٍِ حعشرل اىَشبسمخ فٜ ثحش ثعْ٘اُ رقٌٞٞ اىززاً ٍشٝط ادٗٝخ خفط 
اعزقبدٓ ٗقْبعبرٔ ثفعبىٞخ اىعلاط اىَعطٚ ٗاىَقذً ىٔ. اىجبحضخ غبىجخ ٍبعسزٞش فٜ ميٞخ اىصٞذىخ عبٍعخ اىقذس 
ٗاىٖذف ٍِ اىذساسخ ٕ٘ رقٌٞٞ ٍذٙ رغبٗة اىَشٝط ٗاىززأٍ ثأدٗٝزٔ ٗسؤٝخ اىعلاقخ ثِٞ قْبعبد اىَشٝط 
  ِ  .ٗرأصٞشٕب عيٚ اىززأٍ ثعلاعٔ اُ اٍن
ٍشبسمزل فٜ ٕزا اىجحش رط٘عٞخ ثبىنبٍو ٗرسزطٞع اىشفط, مَب رسزطٞع رشك اعبثخ اٛ سإاه لا ر٘د الاعبثخ عْٔ 
 فبسغب.
ٕ٘ٝزل سزجقٚ ٍغٖ٘ىخ مَب أُ اىجٞبّبد اىزٜ سٞزٌ اىحص٘ه عيٖٞب ىِ رسزخذً ئلا لأغشاض اىجحش اىعيَٜ ٗسزحبغ 
 ثبىسشٝخ اىزبٍخ.
  ٘ ٍْل الاعبثخ عِ الاسئيخ ثذقخ ٍٗ٘ظ٘عٞخ.ارا مْذ ر٘افق عيٚ اىَشبسمخ اسع
 
 شنشا ىزعبّٗنٌ
 اىجبحضخ
 05
 
 عٖبد شنبسّخ
 
 
 
 
 
 
 
 
 
 المعلومات الشخصٌة -1القسم الاول :
  
 ) سنة 16≥(    -4
   )26-65(   -3
        سنة 
 العمر               سنة  ) 24≤(  -1 ) سنة  55-14(   -1
 الجنس                                      ذكر  -1 انثى -1  
بٌت -1 2- الخلٌل 
 لحم
 السكن مكان
-3 عالً تعلٌم-4
 ثانوي
         
         
  
                ابتدائً -1 اعدادي-1
   
                     التعلٌم
 كانت اذا( نعم اعمل  -1  
 :  تحدٌد الرجاء:  بنعم الاجابة
) : الوظٌفة( العمل طبٌعة
.................................
 ..............
 الوظٌفة اعمل لا -1
 ) العمل(
 
-2261( -3 ) شٌكل 2221≥ ( -4
 شٌكل )2221
                   الشهري الدخل ) شٌكل2221≤ (-1 شٌكل  )2251-2221( -1
 الوضع عزباء\اعزب -1                ة\متزوج-1                 ة\مطلق -3 ة\ارمل -4
 :       الاجتماعً
 القسم الثانً :استجابة المرضى والتزامهم بالدواء استنادا للمقٌاس الرابع  للعالم مورنسكً 
 
هل سبق ونسٌت أن تاخذ  -1
 دواءك ؟
نعم ,, كم عدد المرات التً نسٌت فٌها ذلك 
 ...........................
 لا
مهتم (مهمل ) هل أنت غٌر  -1
 بوقت أخذك لدوائك ؟
 نعم ,
 السبب ..................................... 
 لا 
عندما تشعر بأنك أفضل هل  -3
 توقف أخذك لدوائك ؟
 لا نعم 
عندما تشعر أنك  أسوأ  هل  -4
 توقف أخذك لدوائك ؟
 لا  نعم 
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 القسم الثالث (الجزء الاول ): قناعات المرٌض الشخصٌة تجاه المرض والأدوٌة 
 
 -1 
أعارض 
 بشده 
اوافق  -5 اوافق  -4 محاٌد -3 أعارض  -1
 بشدة 
وضعً 
الصحً 
فً 
الوقت 
الحاضر 
, ٌعتمد 
على 
تناولً 
 أدوٌتً .
     
حٌاتً 
سوف 
تكون 
مستحٌلة 
دون 
تناول 
 أدوٌتً .
 
     
بدون 
أدوٌتً 
سأصبح 
 مرٌضا
 للغاٌة .
     
صحتً 
فً 
المستقبل 
تعتمد 
على 
تناول 
 أدوٌتً .
 
     
أدوٌتً 
تحمٌنً 
من أن 
أصبح 
 أسوأ .
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 مخاوف المرٌض تجاه الأدوٌة  :الثالث ( الجزء الثانً )القسم 
الحاجه الى تناول 
 الأدوٌة تقلقنً .
أعار -1
ض 
 بشده 
أوافق بشده  -5 أوافق  -4 محاٌد  -3 أعارض  -1
 .
أحٌانا بالقلق أشعر 
من الاثار الطوٌلة 
 الامد لأدوٌتً .
     
أدوٌتً هً لغز 
 بالنسبة لً .
 
     
أدوٌتً تعطل 
 حٌاتً .
 
 
 
      
أقلق فً بعض 
الاحٌان أن أصبح 
معتمدا جدا على 
 أدوٌتً .
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 (التارٌخ المرضً ).ة للمرضى متعلقة بالعلاج والمرض القسم الرابع :اسئلة موجه
مدة المرض 
 (سنة)
 1> -1
 سنة
-1( -2
 )سنة5
-6( -3
)س11
 نة
  سنة 11< -4
اذا كنت 
تستخدم ادوٌة 
لخفض الدهون 
,الرجاء ذكرها 
 ؟
     
ارتفا -1 أمراض أخرى
ع 
الضغ
 ط
تصلب  -2
القلب 
والشراٌٌ
 ن
أمراض  -4 سكري -3
أخرى لم 
 ٌتم ذكرها
 لا -5
هل ٌعانً أحد 
افراد عائلتك 
من امراض 
القلب 
 ؟والشراٌٌن 
 
    لا -2 نعم -1
نعم     ,الفترة الزمنٌة  -1 مدخن
 للتدخٌن .............
تركت -3 لا -2
التدخٌن منذ 
 ...............
ممارسه 
 الرٌاضة
 
  لا -2 نعم -1
-15 -1 محٌط الخصر
16
 سم
-17 -3 سم 17-16 -2
 18
 سم
س19< -5 سم 19-18 -4
 م
15( -1 الوزن
-
11
)ك1
 غم
-111( -2
 )كغم151
< -3
51
ك1
 غم
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Appendices C: 
 
MMAS-4 Yes No 
 Do you ever forget to take 
medication? 
      
 Are you carless at times about taking 
your medication? 
  
 When you feel better, do you 
sometimes stop taking your 
medication? 
  
 Sometimes ,if you feel worse when 
take your medicine do you stop 
taking it?  
  
 
      لا     ُعٔ يىسٔسِٛ طايمِ 
  1- ؟ نءاٚد زخأح ْأ جيسٔٚ كبس ً٘ 
  2- ؟ هئاٚذٌ نزخأ ثالٚأب ًِّٙ جٔأ ً٘ 
  3-  نزخأ فلٛح ً٘ , ٓسحخٌاب شعشح اِذٕع
؟ أايحأ هئاٚذٌ 
  4-  أٛسأ هٔأب ثشعش ارا ْايحلاا ضعب يف
؟ ٗفلٛح ً٘ نءاٚد زخأح اِذٕع 
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Appendices D: 
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  باٌذٚاء بالخٕاعُٙ ٚحأثشٖ اٌّٛصٛف بعلاجُٙ اٌىٌٛيسخشٚي خفض أدٚيت ِشضى اٌخضاَ حمييُ
  اٌفٍسطيٕيت اٌصحت ٚصاسة في  اٌغشبيت اٌضفت في الله ساَ ٚ ٌحُ بيج ِٕاطك في
  جٙاد خٍيً احّذ  شىاسٔت اعذاد :
  اٌحلاق حسيٓ اٌذوخٛس اٌّششف:
  :اٌٍّخص
 اٌّمذِت
لاسزخذاً ادٗٝٔ خفط اىذُٕ٘ ععو عذد ٍشظٚ اىن٘ىٞسزشٗه ٝززاٝذ سْ٘ٝب  اىززاً اىَشٝط فقش
عيٚ اىشغٌ ٍِ الأدىخ اىق٘ٝخ اىزٜ رشثػ اىَشض ثبعزجبسٓ ٍإشش خطٞش ٗ عبٍو ٍسبعذ ٗ ٍسجت 
 اسبسٜ فٜ حذٗس اىغيطبد اىقيجٞخ ٗ اٍشاض اىقيت. 
رجِٞ اىعلاقخ ثِٞ اىززاً اىَشٝط ٗ رأصشٓ ْٕبك عذد ٍحذٗد ٍِ اىذساسبد فٜ عَٞع اّحبء اىعبىٌ 
ثبقزْبعٔ ثبىذٗاء ٗ اىعلاط اىَ٘ص٘ف ىٔ ىخفط اىن٘ىٞسزشٗه ىزىل رٌ اعشاء ٕزٓ اىذساسخ ىفحص 
  .ٍذٙ اىززاً اىَشٝط ٗ رأصٞشٓ عيٚ اسزغبثزٔ ىذٗائٔ اىَ٘ص٘ف ىٔ
 
 الا٘ذاف
ثأدٗٝزٌٖ ٗ ٕ٘ رقٌٞٞ ٍسز٘ٙ اىززاً ٍشظٚ اىن٘ىٞسزشٗه  اىذساسخمبُ اىٖذف ٍِ ٕزٓ 
ٞح اىعلاقخ ثِٞ اىززاً اىَشظٚ رأصٞش قْبعبرٌٖ عيٚ اىززاٌٍٖ ثٖزٓ الادٗٝخ . ٗ ر٘ظ
ثذٗائٌٖ ٗ اىَزغٞشاد اىذَٝ٘غشافٞخ ٗ اىسشٝشٝخ الاخشٙ اىَزعيقخ ثبىَشبسمِٞ فٜ 
  .اىذساسخ 
 
 الأساٌيب
ىزقٌٞٞ رأصٞش  9102ٗٝ٘ىٞ٘  9102ثِٞ ْٝبٝش اعشٝذ دساسٔ ٍسزعشظخ فٜ اىفزشح  ٍب 
ٍعزقذاد اىَشظٚ  ح٘ه الأدٗٝخ ٗاىع٘اٍو اىذَٝ٘غشافٞخ ٗاىسشٝشٝخ اىزٜ رإصش عيٚ 
  خفط اىن٘ىسزشٗه. ثأدٗٝخرقٞذٌٕ 
أعشٝذ ٕزٓ اىذساسخ فٜ عٞبداد اىشعبٝخ اىصحٞخ الأٗىٞخ اىحنٍ٘ٞخ فٜ ٍذْٝزٜ ساً 
ٍ٘سسنٜ  ىلاىززاً  بلأدٗٝخ  ثبسزخذاً ٍقٞبسٗ رٌ قٞبس ٍذٙ الاىززاً ثالله ٗثٞذ ىحٌ.
). ٗقذ رٌ رحيٞو اىْزبئظ ثبسزخذاً ثشّبٍظ اىحزٍخ الإحصبئٞخ 4-SAMMثبىذٗاء  (
 ). )SSPSىيعيً٘ الاعزَبعٞخ 
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 إٌخائج
ٍشٝعب ًعيٚ اىَشبسمخ فٜ  581ٍشٝعب ًرٌ رْبٗىٌٖ ، ٗافق ٍب ٍغَ٘عٔ  022ٍِ ثِٞ 
سة ب) ٍِ اىشعبه. مبُ ٍب ٝق%3.75( 601ٌٍْٖ ٪). 1.48اىذساسخ ثَعذه اسزغبثخ (
 سْخ. 65≥ ٪)  5.64( 88ٍِ ّصف اىَشبسمِٞ 
 
، مبُ عذً الاىززاً ثبلأدٗٝخ ٍشرفًعب  eniveL-neerG-yksiroMٗفقًب ىَقٞبس   
٪) ٝإٍُْ٘ ثعشٗسح علاعٌٖ ىيحفبظ 5.56غبىجٞخ اىَشبسمِٞ ( حٞش أُ  ٪).6.74(
 عيٚ صحزٌٖ اىغٞذح.
 
ٍزغٞشاد لا رزاه مجٞشح ٗرشرجػ ٍع عذً  4ٍزعذد اىَزغٞشاد أُ أظٖش الاّحذاس 
  81.3 = RO(، اىصٞذىٞخ  )30.0 = P؛  9.0 :IC-  3.4؛ 25.2 = RO(الاىززاً. 
  P؛ 2.2 :IC- 6.4؛  01.3 = RO(، ىذٖٝب ٍشض  )700.0 = P؛ 9.1 :IC- 7.5؛
 P،   1.1 :IC-6.4؛  98.2 = RO(ٗع٘د ٍخبٗف ثشأُ اٟصبس اىغبّجٞخ ) 500.0 =
 .مبّ٘ا عيٚ الأسعح غٞش ٍيززٍِٞ ثأدٗٝزٌٖ )40.0 =
 
 الاسخٕخاج
مبُ عذد اىَشظٚ اىغٞش ٍيززٍِٞ ثزْبٗه ادٗٝٔ خفط اىذُٕ٘ عبىٜ, ٗ ٗعذ اُ ٍعظٌ 
ٍشظٚ خيو اىن٘ىٞسزشٗه ىذٌٖٝ اعزقبد اٝغبثٜ ثعشٗسح أخزٌٕ ىيذٗاء, ٗ عيٚ اىشغٌ 
غبٓ اىذٗاء  ٍشرفع اٝعب . ىزىل ٝغت عيٚ ٍِ رىل فبُ ٍسز٘ٝبد ٍخبٗف اىَشظٚ ار
الاغجبء رحذٝذ ٗ اسزٖذاف اىَشظٚ اىَعشظِٞ ىَخبغش عبىٞخ ٗ رخصٞص خطخ 
 اىعلاط اىخبصخ ىٌٖ ٍِ أعو اى٘ص٘ه ثسٞطشح مبفٞٔ عيٚ عذً الاىززاً ىٖزٓ الأدٗٝخ.
 
 
 
 
 
 
 
